Published in N Engl J Med on October 12, 1995
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet (2004) 1.96
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut (2007) 1.68
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65
Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst (2010) 1.57
Update on familial pancreatic cancer. Adv Surg (2010) 1.54
Detecting early pancreatic cancer: problems and prospects. Semin Oncol (2007) 1.54
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol (1998) 1.46
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Genetic alterations in pancreatic carcinoma. Mol Cancer (2003) 1.43
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Genetic susceptibility to pancreatic cancer. Mol Carcinog (2012) 1.36
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30
Familial pancreatic cancer--current knowledge. Nat Rev Gastroenterol Hepatol (2012) 1.27
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Mouse models of pancreatic cancer. World J Gastroenterol (2012) 1.20
CDKN2A germline mutations in familial pancreatic cancer. Ann Surg (2002) 1.18
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet (2010) 1.08
Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci (2013) 1.06
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol (1999) 1.04
Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet (2003) 1.03
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol (2014) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut (2005) 1.02
Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet (2014) 1.01
MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet (2005) 1.00
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med (2014) 0.97
Inherited predisposition to pancreatic cancer. Gut (2001) 0.97
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst (2012) 0.96
Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol (2004) 0.96
Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet (1996) 0.96
Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome. Cancer Epidemiol Biomarkers Prev (2010) 0.95
Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol (2014) 0.95
Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther (2009) 0.95
Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. Cancer Epidemiol Biomarkers Prev (2014) 0.95
Genetic predisposition to pancreatic cancer. World J Gastroenterol (2014) 0.94
Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res (2009) 0.94
Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut (2004) 0.94
Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS One (2013) 0.92
Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.91
Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci (2010) 0.91
Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci (2015) 0.91
Association of breast cancer susceptibility variants with risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.90
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer (2001) 0.90
Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev (2015) 0.89
Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer (2010) 0.88
Identification of germline genetic mutations in patients with pancreatic cancer. Cancer (2015) 0.87
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet (2000) 0.86
Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) (2010) 0.86
A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Res (2015) 0.86
Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer (2003) 0.85
Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Cancer Lett (2012) 0.85
Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. Dermatol Res Pract (2009) 0.85
Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet (1996) 0.84
Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet (2008) 0.84
Familial pancreatic carcinoma in Jews. Fam Cancer (2004) 0.83
Familial melanoma and pancreatic cancer. N Engl J Med (1996) 0.83
Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. Gynecol Oncol (2011) 0.83
Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs (2000) 0.82
Undifferentiated carcinoma with osteoclastic giant cells (UCOCGC) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM). Am J Surg Pathol (2008) 0.82
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
Hereditary pancreatic and hepatobiliary cancers. Int J Surg Oncol (2011) 0.81
The molecular biology of pancreatic cancer. Gastrointest Cancer Res (2007) 0.81
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets (2015) 0.81
Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br J Cancer (2004) 0.81
Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs (2003) 0.81
Familial pancreatic cancer. Fam Cancer (2004) 0.81
Case-only exome sequencing and complex disease susceptibility gene discovery: study design considerations. J Med Genet (2014) 0.80
Diabetes mellitus in pancreatic cancer patients in the Czech Republic: sex differences. Exp Diabetes Res (2012) 0.80
Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg (2010) 0.80
Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther (2007) 0.80
Study human pancreatic cancer in mice: how close are they? Biochim Biophys Acta (2012) 0.80
Gene expression profile analysis of pancreatic cancer based on microarray data. Mol Med Rep (2016) 0.80
Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl J Med (1996) 0.79
Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol (2015) 0.79
Familial malignant melanoma - overview. Hered Cancer Clin Pract (2004) 0.79
Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol (2016) 0.78
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Review of screening for pancreatic cancer in high risk individuals. World J Gastroenterol (2011) 0.78
Risk of other cancers in individuals with a family history of pancreas cancer. J Gastrointest Cancer (2007) 0.77
Familial pancreatic cancer--status quo. Int J Colorectal Dis (2013) 0.77
Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol (2011) 0.77
Familial association of pancreatic cancer with other malignancies in Swedish families. Br J Cancer (2009) 0.76
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
A genetic map of the mouse suitable for typing intraspecific crosses. Genetics (1992) 8.53
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest (1984) 3.86
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
THE CLINICAL EVALUATION OF AUREOMYCIN. J Clin Invest (1949) 3.60
Isolation and chromosomal assignment of 100 highly informative human simple sequence repeat polymorphisms. Genomics (1992) 3.42
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet (1996) 2.96
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol (1978) 2.81
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A (1989) 2.25
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
The developmental biology of primary human malignant melanomas. Semin Oncol (1975) 1.92
Premarital sex, schoolgirl pregnancy, and school quality in rural Kenya. Stud Fam Plann (2001) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Progress in high throughput SNP genotyping methods. Pharmacogenomics J (2002) 1.88
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA (1978) 1.74
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Mutations associated with familial melanoma impair p16INK4 function. Nat Genet (1995) 1.69
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
Familial testicular cancer and urogenital developmental anomalies. Cancer (1985) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (1999) 1.61
The kin-cohort study for estimating penetrance. Am J Epidemiol (1998) 1.60
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
Hyperendemic Streptococcus pyogenes infection despite prophylaxis with penicillin G benzathine. N Engl J Med (1991) 1.57
Evidence for human meiotic recombination interference obtained through construction of a short tandem repeat-polymorphism linkage map of chromosome 19. Am J Hum Genet (1993) 1.57
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Primary malignant melanoma of the urinary bladder. Cancer (1976) 1.48
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst (2000) 1.45
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. Mol Psychiatry (2003) 1.42
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol (1986) 1.34
Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet (1986) 1.34
Malignant melanoma in renal-transplant recipients. Lancet (1981) 1.33
A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene (2011) 1.29
Somatic cell genetic analysis of human cell surface antigens: chromosomal assignments and regulation of expression in rodent-human hybrid cells. Proc Natl Acad Sci U S A (1984) 1.27
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
A fine-structure study of the human epidermal melanosome complex and its acid phosphatase activity. J Ultrastruct Res (1968) 1.26
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21
Role of human chromosome 11 in determining surface antigenic phenotype of normal and malignant cells. Somatic cell genetic analysis of eight antigens, including putative human Thy-1. J Exp Med (1985) 1.19
Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol (1979) 1.18
Prevalence of Toxoplasma gondii antibodies in US military recruits in 1989: comparison with data published in 1965. Clin Infect Dis (1996) 1.18
Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18
Identification of a new murine runt domain-containing gene, Cbfa3, and localization of the human homolog, CBFA3, to chromosome 1p35-pter. Genomics (1995) 1.17
Progressive arterial occlusive disease (Köhlmeier-Degos). A frequently fatal cutaneosystemic disorder. N Engl J Med (1967) 1.17
Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet (2000) 1.16
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet (1984) 1.15
A locus for Fanconi anemia on 16q determined by homozygosity mapping. Am J Hum Genet (1996) 1.15
Restriction analysis of the structural alpha-L-fucosidase gene and its linkage to fucosidosis. Am J Hum Genet (1988) 1.14
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13
Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet (1980) 1.12
Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol (1984) 1.11
Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet (2004) 1.10
Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol (1999) 1.10
Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol (1979) 1.10
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res (1987) 1.09
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet (1993) 1.08
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res (1989) 1.07
Genetic and physical map of the interferon region on chromosome 9p. Genomics (1992) 1.07
Full-genome scan for linkage in 50 families segregating the bipolar affective disease phenotype. Am J Hum Genet (2000) 1.05
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer (1975) 1.05
Expression of DR antigens in freshly frozen human tumors. Hybridoma (1982) 1.05
The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol (1993) 1.03